News
Tubilux Pharma Upgrades with Steriline Aseptic Filling Line
Steriline has completed the delivery and installation of a fully integrated aseptic filling line at a manufacturing facility operated by Tubilux Pharma. The system is designed to process both plastic and glass vials, supporting applications ranging from eye drops...
Business & Industry
Regeneron Telix Radiopharma Deal Targets Cancer Therapies
Regeneron Pharmaceuticals has entered into a strategic agreement with Telix Pharmaceuticals to jointly develop next-generation oncology treatments, in a deal valued at up to $2.1 billion in milestone payments. The radiopharma collaboration will combine Regeneron’s antibody-based discovery capabilities with...
News
Overqualified and Underutilized: The Hidden Risk in Physician Hiring
Hospitals brag about “top talent,” then act stunned when that talent starts shopping for the exit. The quiet disaster in physician hiring usually stems from something other than credential issues. It comes from an excess of them. A clinician...
Business & Industry
Drug Manufacturing Deals Shift to Europe Despite Tariffs
Biopharma companies are continuing to redirect production strategies toward Europe, even as U.S. policymakers attempt to strengthen domestic output through tariffs and onshoring measures. According to GlobalData, the latest data highlights a clear divergence in deal activity, with drug...
BioPharma
DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology
DeepCyte, a techbio company focused on advancing AI Drug Toxicology, has launched with $1.5 million in seed funding. The company is introducing two integrated solutions aimed at helping biopharma teams detect, predict, and explain drug toxicity directly in human...
Business & Industry
Hypercon Technology Deal Signed between Halozyme and Vertex
Halozyme Therapeutics has entered into a global exclusive partnership and licence agreement with Vertex Pharmaceuticals through its subsidiary Halozyme Hypercon, marking a new step in advancing drug delivery capabilities. The deal gives Vertex access to the Hypercon platform, which...
Business & Industry
Gilead Advances ADC Pipeline Expansion with $3B Tubulis Deal
Gilead Sciences has agreed to acquire Germany-based Tubulis in a deal valued at $3.15 billion upfront, with an additional $1.85 billion tied to milestones, as the company advances its position in the rapidly evolving antibody-drug conjugate segment. The acquisition...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read